You are here
SBIR TOPIC 251: DEVELOPMENT OF ANTICANCER AGENTS REQUESTOR: ALI ANDALIBI VEN
Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: N43CM0800027
Agency Tracking Number: N43CM0800027
Amount:
$185,073.00
Phase:
Phase I
Program:
SBIR
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Timeline
Solicitation Year:
2008
Award Year:
2008
Award Start Date (Proposal Award Date):
N/A
Award End Date (Contract End Date):
N/A
Small Business Information
GENESEGUES, INC.
3180 HIGH POINT DRIVE
CHASKA, MN
55318
United States
DUNS:
095972415
HUBZone Owned:
No
Woman Owned:
No
Socially and Economically Disadvantaged:
No
Principal Investigator
Name: Gretchen Unger
Phone: () -
Phone: () -
Business Contact
Phone: (952) 443-3798
Email: rtu@genesegues.com
Email: rtu@genesegues.com
Research Institution
N/A
Abstract
Metastatic spread of cancer cells is the primary cause of death in cancer patients and developing therapeutic agents that kill primary and disseminated cancer cells is an important topic. The aim of this project is to continue the development of a novel nanocapsule for the delivery of RNAi into tumor cells. Necessary studies to support the filing of an IND will be conducted. Potential off-targeting properties of the nanoencapsulated therapeutic will be investigated in tissue specimens.
* Information listed above is at the time of submission. *